Osmotic-Release Methylphenidate for ADHD in Adolescents with Substance Use Disorders
Paula Riggs, MD Principal Investigator University of Colorado at Denver Health Sciences Center 4200 E. 9th Ave. Denver, CO 80262 paula.riggs@uchsc.edu

ADHD is one of the most common co-occurring psychiatric disorders in adolescents with substance use disorders. Several studies indicate that up to one-half of the adolescents in substance treatment programs have ADHD, which is associated with more severe substance abuse and behavior problems, as well as poorer treatment retention and outcomes when compared to substance-dependent adolescents without ADHD.

The primary objectives of this study are to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder (SUD).  The study will involve approximately 300 participants, recruited from 10 community treatment sites.

  RELATED STUDIES

• CTN-0028-A-1: Does Methylphenidate Treatment for ADHD Increase the Rate of Smoking in Adolescents with Comorbid ADHD, Substance Use Disorder, and Nicotine Dependence?

	Find publications in the Library about Protocol CTN-0028